Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - porcine parvovirus, strain s-80 inactivated, erysipelothrix rhusiopathiae suis, strain b-7 (serotype2) inactivated - emulsion for injection - unknown - inactivated porcine parvovirus vaccine + inactivated erysipelothrix vaccine - porcine - immunological - inactivated vaccine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - inactivated rabies virus -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - inactivated,influenza virus type a (h3n2); inactivated,influenza virus type a (h1n1); inactivated,influenza virus type b (b/victoria); inactivated,influenza virus type b (b/yamagata) -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbott laboratories (m) sdn. bhd. - inactivated,influenza virus type a (h1n1); inactivated,influenza virus type a (h3n2); inactivated,influenza virus type b (b/yamagata); inactivated,influenza virus type b (b/victoria) -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aj biologics sdn. bhd. - inactivated,influenza virus type a (h1n1); inactivated,influenza virus type a (h3n2); inactivated,influenza virus type b (b/victoria) -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aj biologics sdn. bhd. - inactivated,influenza virus type a (h1n1); inactivated,influenza virus type a (h3n2); inactivated,influenza virus type b (b/victoria) -

Philippines - English - FDA (Food And Drug Administration)

zoetis philippines, inc.; distributor: zoetis philippines, inc. - inactivated newcastle disease (nd) virus vaccine (vet.) - emulsion for injection (sc) - formulation: each 0.1 ml (dose) contains: newcastle disease virus (b1 type, la sota strain)....>1:32 hi titer hi – hemagglutination inhibition

United States - English - NLM (National Library of Medicine)

a-s medication solutions - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually an immunization series is initiated and completed with 1 vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv.4,11 preexposure vaccination: see table 1 and dosage and administration. preexposure vaccination consists of 3 doses of rabavert 1.0 ml given intramuscularly (deltoid region), 1 each on days 0, 7, and 21 or 281 (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see dosage and administration: postexposure prophylaxis of previously im

Canada - English - Health Canada

sanofi pasteur limited - rabies vaccine inactivated (human diploid-cell culture) - powder for suspension - 2.5unit - rabies vaccine inactivated (human diploid-cell culture) 2.5unit - vaccines

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - powder and suspension for suspension for injection - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens